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Abstract
Cytochrome P4502D6, an important isoform of cytochrome P450, mediates the metabolism of several psychoactive drugs in liver.
Quantitatively, liver is the major drug metabolizing organ, however metabolism of drugs in brain could modulate pharmacological and
pharmacodynamic effects of psychoactive drugs at their site of action and explain some of the variation typically seen in patient
population. We have measured cytochrome P450 content and examined constitutive expression of CYP2D mRNA and protein in human
brain regions by reverse transcription polymerase chain reaction, Northern and immunoblotting and localized it by in situ hybridization
and immunohistochemistry. CYP2D mRNA was expressed constitutively in neurons of cerebral cortex, Purkinje and granule cell layers of
cerebellum, reticular neurons of midbrain and pyramidal neurons of CA1, CA2 and CA3 subfields of hippocampus. Immunoblot studies
demonstrated the presence of cytochrome P4502D protein in cortex, cerebellum, midbrain, striatum and thalamus of human brain.
Immunohistochemical localization showed the predominant presence of cytochrome P4502D not only in neuronal soma but also in
dendrites of Purkinje and cortical neurons. These studies demonstrate constitutive expression of cytochrome P4502D in neuronal cell
population in human brain, indicating its possible role in metabolism of psychoactive drugs directly at or near their site of action, in
neurons, in human brain.  2002 Elsevier Science B.V. All rights reserved.
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1 . Introduction induced or inhibited by a variety of drugs, are known to
exist in liver, the major organ involved in P450 mediated
Cytochrome P450 (E.C. 1.14.14.1; P450) and associated metabolism [7]. In the recent years, P450-mediated metab-
monooxygenases are the principal class of drug metaboliz- olism in extrahepatic organs (such as lung, kidney, skin,
ing enzymes. This family of heme-protein is encoded by a nasal epithelium) and the far-reaching consequences of
supergene family, and the member proteins exist in such metabolism, in situ, within specific cells in target
multiple forms having distinct yet overlapping substrate organs have been recognized in laboratory animals [10]
specificities. Multiple forms of P450, which are selectively and humans [20].
Psychoactive drugs such as antidepressants and neuro-
leptics are known to be metabolized by hepatic P450. The
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metabolism of psychoactive drugs in both rat and human labeling and detection kit, anti-digoxigenin fab fragments
liver belong to P4503A, 2D, 2C and 1A families. P4502D6 linked to peroxidase and alkaline phosphatase were pur-
is a constitutive form of hepatic P450 in human. Isoforms chased from Boehringer Mannheim, USA. The tyramide
of P450 belonging to the 2D family are identifiable in rat signal amplification (indirect) kit for in situ hybridization
and human liver where they mediate the metabolism of was obtained from New England Nuclear, USA and
several commonly used psychoactive drugs, such as imi- Vectastain-ABC Elite kit was purchased from Vector Labs.,
pramine, amitryptaline and chlorimipramine [4,9] and USA. All other chemicals and reagents were of analytical
haloperidol [34]. grade and were obtained from Sigma (St. Louis, MO,
The hepatic metabolism of drugs and the genetic poly- USA) or Qualigens, India.
morphism exhibited by some forms of P450 are generally
understood. These variables are reflected in the plasma 2 .2. Animals
levels of administered drugs. However, plasma drug levels
often show poor correlation with therapeutic effect [13] Male Wistar rats (3–4 months, 225–250 g) were ob-
suggesting that metabolism within the brain could in- tained from the Central Animal Research Facility of
fluence the therapeutic outcome regardless of hepatic NIMHANS. Animals had access to pelleted diet and water
clearance and plasma drug levels. A moderate difference in ad libitum. All animal experiments were carried out in
the pharmacokinetics of psychoactive drugs often leads to accordance with the National Institutes of Health guide-
dramatic pharmacodynamic effects, again suggesting that lines for the care and use of laboratory animals. All efforts
metabolism in situ within the brain could play a significant were made to minimize animal suffering, to reduce number
role [3]. of animals used and to utilize alternatives to in vivo
Recent studies have shown metabolic activity of P450 techniques, if available.
isoforms in rat and human brain microsomes using specific
substrates including some psychotropic drugs. These 2 .3. postmortem studies
studies have demonstrated the biotransformation of imi-
pramine to desipramine and hydroxyimipramine [31], and Rats were sacrificed by cervical dislocation and the
dextromethorphan to dextrorphan in rat brain microsomes animals were kept at 20 8C for different time periods (6, 12
[12]. The presence of dextromethorphan-O-demethylase and 24 h). At the end of each predetermined time period,
activity in rat and human brain microsomes have also been animals were decapitated and liver and brain were re-
confirmed by studies from other laboratories using specific moved rapidly. Control animals were sacrificed by cervical
inhibitors and antibodies to P4502D6 [36]. These studies dislocation and the liver and brain removed immediately.
have also demonstrated the low metabolic activity of The tissues were processed immediately for isolation of
P4502D6 in human brain microsomes and the need for total RNA [6] or preparation of microsomes [26].
addition of exogenous NADPH cytochrome P450 reduc-
tase for detecting the monooxygenase activity. 2 .4. Studies with human brain
Over the past decade, our laboratory and others have
demonstrated the presence of P450 mediated monooxy- Human brains from traffic accident victims with no
genase activities in rat and human brain and examined the known neuro-psychiatric disorders were obtained from the
metabolism of a variety of model substrates [27]. Of the Human Brain Tissue Repository, Department of Neuro-
several isoforms of P450 that are expressed constitutively pathology, NIMHANS. Both male and female brains were
in rat brain, P4502D4 is expressed in significantly higher used. The gender, age of the deceased and postmortem
amounts in brain as compared to other tissues including the delay are given in Table 1. After autopsy, brains were
liver [15]. In humans, the relative amounts of the different washed in ice-cold saline and dissected into different
isoforms of P450 and their localization are as yet unclear. regions such as cortex, hippocampus, striatum, midbrain,
In view of the important role that P4502D plays in the cerebellum and thalamus based on standard anatomical
metabolism of psychoactive drugs, we have investigated markings. All regions were flash frozen and stored at
the expression of P4502D in human brain and localized the 270 8C immediately. Regions from each human brain was
expression of this isoform of P450 using fluorescence in thawed on ice and used for the preparation of microsomes
situ hybridization and immunohistochemistry. as described below. Microsomes were aliquoted and stored
at 270 8C and used for assaying P450 content.
2 . Materials and methods 2 .5. Preparation of microsomes
2 .1. Materials All steps were performed at 4 8C. Rat brain or human
brain tissue was homogenized using a Potter–Elvehjem
cDNA to CYP2D6 and antiserum to P4502D1 were homogenizer in nine volumes of ice-cold Tris buffer (0.1
obtained as gifts from Dr. J.P. Hardwick. DIG-RNA M, pH 7.4) containing dithiothreitol (0.1 mM), EDTA (0.1
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Table 1
Specific content of P450 in human brain regions
Subject Gender Age Postmortem Specific content (nmole P450/mg protein)
(years) delay (h) Cortex Cerebellum Striatum Thalamus
I Female 8 8 0.036 0.043 0.024 0.034
II Male 65 6 0.023 0.022 0.025 0.028
III Female 28 12 0.020 0.021 0.028 0.031
Mean6S.D. 0.02660.008 0.03160.01 0.02660.002 0.03160.003
Cytochrome P450 content was measured from the reduced minus oxidized carbon monoxide binding spectrum in human brain regions obtained at autopsy
from three subjects. Values are average of two measurements performed using two different concentrations of microsomal protein.
mM), KCl (1.15%, w/v), phenylmethylsulfonyl fluoride Regions from human brain (cortex, cerebellum, midbrain
(0.1 mM), butylated hydroxytoluene (22 mM) and glycerol and hippocampus) were dissected out and fixed in buffered
(20%, v/v), previously bubbled with nitrogen (buffer A). paraformaldehyde. The tissue was processed for paraffin
The homogenate was centrifuged at 17,000 g for 30 min at embedding, serial sections (8–10 mm thick) were cut under
4 8C. Thereafter, the supernatant was centrifuged at RNase-free conditions. Sections were dewaxed, hydrated
100,000 g for 1 h at 4 8C to give the microsomal pellet in graded ethanol, acetylated and treated with proteinase K
[26]. The pellet was washed, suspended in a small volume (100 mg/ml) for 20 min at 37 8C. The sections were rinsed
of buffer A, aliquoted and stored at 270 8C. Protein in phosphate-buffered saline (PBS) and dehydrated using
concentration was measured by a dye-binding method [2]. graded ethanol. Digoxigenin-labeled sense (for control
Total P450 content was measured from the carbon monox- sections) and antisense cRNA probes were synthesized
ide reduced minus oxidized difference spectrum [18]. from cDNA to CYP2D6 using T3 and T7 RNA poly-
merases. Sections were hybridized overnight at 55 8C with
2 .6. Immunoblot analysis the sense or antisense probes. After hybridization, the
sections were washed, blocked with 0.5% (w/v) bovine
Microsomal protein from human brain regions were serum albumin (NEN Life Sciences Products, USA) and
subjected to sodium dodecyl sulfate–polyacrylamide gel incubated with antibody to digoxigenin fab fragments
electrophoresis (SDS–PAGE) [16]. Proteins were trans- conjugated to horseradish peroxidase. After washing, the
ferred from the gel to nitrocellulose paper [33] and sections were incubated with biotinylated tyramide (NEN
incubated with the antiserum to rat liver P4502D1, fol- Life Sciences Products) followed by FITC labeled strep-
lowed by incubation with anti-rabbit IgG labeled with tavidin. Finally the sections were washed, dried and
alkaline phosphatase. The immunostained bands were mounted prior to examination under a fluorescence micro-
detected using nitroblue tetrazolium and 5-bromo-4-chloro- scope.
3-indolyl phosphate as chromogenic substrates for alkaline
phosphatase. 2 .8. Reverse transcription polymerase chain reaction
(RT-PCR) analysis of mRNA from human brain cortex
2 .7. Northern analysis and fluorescence in situ
hybridization Total RNA was isolated from frontal cortex of autopsy
human brain samples as described above. The first strand
The cDNA to CYP2D6 provided by Dr. James Hard- of cDNA was synthesized using 1 mg of total RNA from
wick [8] was subcloned into pBluescript, verified by DNA human brain, oligo dT primers and reverse transcriptase.
sequencing and used for preparation of riboprobes. Total The second strand was synthesized using T4 DNA poly-
RNA from rat liver, brain and human frontal cortex was merase. The double-stranded DNA was purified by phenol /
extracted as described by Chomezynski [6]. Total RNA chloroform extraction and alcohol precipitation. The
was separated electrophoretically and transferred onto primer sequences, nucleotide location, expected product
positively charged nylon membranes by capillary transfer size and Genebank accession numbers for CYP2D6 and
[14]. After UV crosslinking, the membranes were hybrid- b-actin are as follows: The primers used for CYP2D6
ized overnight at 55 8C with the digoxigenin-labeled (Genebank accession number5M20403) analysis were 59
antisense riboprobe prepared using the cDNA to CYP2D6, to 39-TGATGAGAACCTGCGCATAG (representing bases
washed, incubated with antibody to digoxigenin fab frag- from 1207 to 1186) and 39 to 59-ACCGAT-
ments conjugated with alkaline phosphatase. The bands GACAGGTTGGTGAT (representing bases from 875 to
were visualized using nitroblue tetrazolium salt and 5- 892) and the expected size of the PCR product is 333 bp.
bromo-4-chloro-3-indolyl phosphate as chromogenic sub- The primers used for b-actin (Genebank accession
strates for alkaline phosphatase. number5X00351) were 59 to 39-TGACGGGGTCAC-
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CCACACTGTGCCCATCTA (representing bases from (8–10 mm thick) were cut. Sections were dewaxed by
1038 to 1067) and 39 to 59-CTAGAAGCATTGCGGT- heating at 70 8C, followed by xylene treatment and brief
GGACGATGGAGGG (representing bases from 1876 to wash in chloroform to remove residual xylene. To block
1905) and the expected PCR product size is 661 bp [23]. endogenous peroxidase reaction, the sections were exposed
RT-PCR analysis of b-actin was carried out simultaneous- to methanol containing hydrogen peroxide (3%, v/v) for
ly as a positive control. The cDNA synthesized from 1 mg 30 min. They were hydrated in graded alcohol followed by
of RNA was suspended in 5 ml of 10 mM Tris–HCl (pH brief wash in water and phosphate buffered saline (10 mM,
8.3) and added to the final reaction mixture which con- pH 7.4, PBS). The sections were placed in metal racks and
tained 50 mM KCl, 200 mm of each dNTP, MgCl (2.5– lowered into the boiling sodium citrate buffer (pH 6.8) and2
3.5 mM), primers (80–85 pmole) and 0.25 units of pressure cooked for 10 min. After cooling, the slides were
AmpliTaq DNA polymerase. The following thermal cy- transferred to PBS. To minimize the binding of non-
cling conditions were used for b-actin, initial denaturation specific proteins, sections were incubated in normal goat
at 94 8C for 5 min followed by 40 cycles consisting of 48 s serum for 30 min at room temperature. The sections were
at 94 8C, 48 s at 68 8C and 1.5 min at 72 8C with a final then washed in PBS and incubated with antiserum to
extension at 72 8C for 10 min. The thermal cycling P4502D1 (diluted to 1:1000 in PBS) at 37 8C for 2 h. After
conditions used for CYP2D6 were as follows: initial washing, they were incubated in biotinylated anti-rabbit
denaturation at 94 8C for 5 min followed by 40 cycles IgG solution (1:500 dilution) for 1 h at room temperature.
consisting of 30 s at 94 8C, 30 s at 68 8C and 60 s at 72 8C
with a final extension at 72 8C for 2 min. The negative
control consisted of sterile water instead of template DNA.
The PCR products (20 ml) were separated by electro-
phoresis using 1.2% agarose gel and stained with ethidium
bromide. The identity of the PCR products was confirmed
by Southern blotting using digoxigenin labeled cDNA to
CYP2D6 and sequencing.
2 .9. Immunohistochemical studies
Human brain obtained at autopsy was dissected out and
fixed in 4% (w/v) buffered paraformaldehyde. The tissue
was processed for paraffin embedding and serial sections
Fig. 2. Dithionite reduced carbon monoxide binding spectrum of micro-
somal P450 from human brain cortex and cerebellum. (A) Microsomes
from cortex region of human brain from subject I was used at a protein
concentration of 0.25 mg/ml. The specific content of P450 in the
Fig. 1. Effect of postmortem delay on P450 content in rat brain and liver. microsomes was estimated to be 0.034 nmole of P450/mg protein. (B)
P450 content was estimated in microsomes prepared from (A) whole Dithionite reduced carbon monoxide binding spectrum of human brain
brain or (B) liver of rats sacrificed after various periods of postmortem cerebellum (subject I) is depicted. The protein concentration was 0.25
delay (6, 12 and 24 h). Values are mean6S.D. (n53 animals). Asterisks mg/ml and the specific content of P450 was estimated to be 0.043 nmole
indicate the values that are significantly different from controls (P,0.05). of P450/mg protein.
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Fig. 3. Northern blot analysis of (A) effect of postmortem delay on CYP2D mRNA in rat brain and liver and (B) human brain total RNA using cDNA to
CYP2D6. (A) Total RNA was extracted from liver (lanes 1, 2 and 3; 5 mg each) and whole brain (lanes 4, 5 and 6; 12 mg each) of rats sacrificed after
various periods of postmortem delay (0, 12 and 24 h) and subjected to Northern blot analysis. The expression of rat liver and brain CYP2D mRNA was
seen as band at approximately 1.6 Kb. (B) Total RNA from rat liver (lane 1, 10 mg) and human brain cortex (lanes 2–4, 15 mg) were electrophoresed
under denaturing conditions. After transfer to nylon membrane, the blots were hybridized with antisense riboprobe prepared using cDNA to CYP2D6. The
total RNA was prepared from cortex of human brain obtained from subjects 1, 2, 3 (lanes 2, 3, 4, respectively). The mobility of the 18S and 28S ribosomal
RNA is indicated The expression of human brain CYP2D mRNA was seen as a band at approximately 1.6 Kb. (C) Analysis of constitutive expression of
CYP2D6 mRNA by RT-PCR. Total RNA was extracted from autopsy human brain cortex. RT-PCR reaction was carried out using primers specific to
b-actin (lane 4) and CYP2D6 isoform (lane 3). Control reaction was performed without template DNA (lane 2). PCR amplified DNA was by agarose gel
electrophoresis and stained with ethidium bromide. The size of the PCR products were 661 bp (for b-actin) and 333 bp for CYP2D6. (D) The PCR
amplified DNA of 333 bp hybridized with digoxigenin labelled cDNA to CYP2D6 as examined by Southern blotting indicating the homology of the
amplified PCR product with CYP2D6.
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After further washing, they were incubated with VECTAS- 3 . Results
TAIN Elite ABC reagent for 30 min at room temperature.
The sections were then washed briefly in PBS followed by 3 .1. Effect of postmortem delay on specific content of
water. The color was developed using diaminobenzidine. P450 in rat brain and liver
The sections were finally washed with water, dehydrated in
graded ethanol, cleared with xylene, air dried and mounted Total P450 content was estimated in brain microsomes
using Permont. of rats sacrificed after various time periods of postmortem
Fig. 4. Localization of CYP2D mRNA in human brain by fluorescence in situ hybridization (A) Fluorescent labeling of the Purkinje cells (arrow) and the
granule cell layer (GL) in human cerebellum indicating the presence of CYP2D mRNA. Sparse staining of the cells in the molecular layer (ML) was also
noted. (B) No staining was seen in section hybridized with the sense probe. Bar5200 mm. (C) Reticular neurons in the midbrain expressed CYP2D
mRNA. Inset: Higher magnification of giant reticular neuron. (D) Control section of midbrain hybridized with the sense probe. Bar5200 mm. (E) Intense
fluorescence was seen in neuronal cell layers of the human brain frontal cortex. Differential fluorescence was seen delineating the laminar architecture of
the cortex (F) Control section hybridized with the sense probe. Bar5200 mm.
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delay. As shown in Fig. 1A, no significant change in brain delay (Fig. 1B). In fact within 6 h, there was 29% loss in
microsomal P450 content was observed even after 24 h of liver microsomal P450 content. These studies indicate the
postmortem delay. The specific content of brain P450 relative stability of brain microsomal P450 to autolytic
varied from 0.09 to 0.1 nmole of P450/mg protein during changes that are known to occur during postmortem. The
the period of examination. In contrast, liver P450 content studies on human brain P450 were hence carried out using
decreased from 0.93 nmole of P450/mg protein to 0.53 human autopsy tissues that were obtained within 12 h of
nmole of P450/mg protein during 24 h of postmortem postmortem delay.
Fig. 5. Localization of CYP2D mRNA in human brain hippocampus using fluorescence in situ hybridization. (A) The presence of CYP2D mRNA was seen
in the pyramidal neurons of CA2 subfield in the hippocampus (arrow). A portion of the dentate gyrus is also seen (double arrow). Bar5400 mm. (B) Higher
magnification of CA2 pyramidal cell layer hippocampus from human brain. Bar5200 mm. (C) Localization of CYP2D mRNA in the granule cell layer of
dentate gyrus (arrow head), CA3 subfield and in the interneurons of hilius (arrow). Bar5400 mm. A similar section hybridized with the sense probe did not
show any fluorescence (D). Bar5200 mm. (E) The presence of CYP2D mRNA was observed in the CA1 pyramidal neurons (arrow). Bar5200 mm.
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Fig. 6. Immunoblot analysis of microsomal protein from human brain regions using antiserum to rat liver P4502D1. Microsomal protein from brain regions
obtained at autopsy from subject 1 were subjected to SDS–PAGE and transferred to nitrocellulose membrane. The blots were immunostained with
antiserum to P4502D1. Immunostained bands were detected at 52 kDa. The lanes contained 50 mg of microsomal protein from cerebral cortex (lane 1),
cerebellum (lane 2), midbrain (lane 3), striatum (lane 4) and thalamus (lane 5).
3 .2. Cytochrome P450 content in human brain regions contrast, in the brain, CYP2D6 mRNA levels did not
change significantly up to 12 h postmortem delay and
Specific content of P450 was estimated in the brain degradation was seen only after 24 h of postmortem delay.
regions of autopsy tissue obtained from three subjects. The This study indicates the relative stability of brain mRNA to
gender, age and time interval between death and autopsy autolytic changes that are known to occur during post-
are given in Table 1. The carbon monoxide reduced minus mortem.
oxidized spectrum of human brain microsomes from cortex
and cerebellum exhibited a characteristic absorption spec-
trum with two peaks at 450 and 425 nm (Fig. 2). The peak 3 .4. Northern blot and RT-PCR analysis of CYP2D
at 450 nm represents P450. The specific content of P450 expression in human brain
was calculated by measuring the absorbance at 450 nm.
P450 measurements varied from 0.02 to 0.04 nmole of Northern blot analysis of total RNA from human brain
P450/mg protein in different regions of the brain from the cortex using the cDNA to CYP2D6 revealed the constitu-
three subjects (Table 1). We were able to procure only four tive expression CYP2D mRNA. The molecular mass of the
regions, namely, cortex, cerebellum, striatum and thalamus transcript was approximately 1.6 Kb which was similar to
for these experiments. P450 content in cerebellum from that seen in rat liver (Fig. 3B). In all the three brain
subject 1 was twofold of that in the striatum. However, this samples the expression of the full-length mRNA to
pattern of distribution was not seen in the other two brains CYP2D was observed. RT-PCR analysis of the cDNA
that were examined. prepared from human brain RNA yielded the expected 333
bp PCR amplified product, confirming the constitutive
3 .3. Effect of postmortem delay on stability of CYP2D6 expression of cytochrome P4502D in the human brain
mRNA in rat brain and liver (Fig. 3C). RT-PCR analysis of b-actin which was carried
out simultaneously as a positive control yielded the
Total RNA was extracted from liver and whole brain of expected product of 661 bp (Fig. 3C). The 333 bp RT-PCR
rats subjected to various time periods of postmortem delay. product was subjected to Southern blotting using the
As shown in Fig. 3A, degradation of CYP2D6 mRNA was digoxigenin labeled cDNA to CYP2D6 and the hybridized
apparent in liver after 12 h of postmortem delay and no band was detected at 333 bp, indicating that the amplified
band was detectable after 24 h of postmortem delay. In product shared homology with CYP2D6 (Fig. 3D). The
Fig. 7. Immunohistochemical localization of P4502D in human brain cerebellum and CA1 area of hippocampus using antiserum to P4502D1. (A)
Localization of 4502D in the granule cells (arrow) and Purkinje cell (double arrow) is depicted. Immunostaining was seen in the plasma membrane as
indicated by the arrowhead. Bar510 mm. (B) Control section incubated with non-immune serum did not show immunostaining in the cerebellum. Bar5100
mm. (C) Immunostaining of CA1 pyramidal neurons indicating the presence of P4502D. Bar510 mm. (D) Similar section treated with non-immune serum
did not show immunostaining of the CA1 neurons. Bar5100 mm.
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sequencing of the RT-PCR product revealed the complete cells, similar to the observation made in the in situ studies.
sequence identity with CYP2D6 in the amplified region. In the Purkinje cell, in addition to the intense punctate
staining seen in the neuronal cell body, the dendritic
3 .5. Localization of CYP2D mRNA in human brain by arborization and synaptic terminals were also significantly
fluorescence in situ hybridization stained. The CA1 neurons in the hippocampus were also
stained although less intensely than in the cerebellum (Fig.
Fluorescence in situ hybridization (FISH) studies dem- 7C). Intense staining of the neuronal cell body and apical
onstrated the presence of CYP2D mRNA predominantly in dendrites was seen in frontal cortex (Fig. 8A). Immuno-
neuronal cells in human brain regions. In the cerebellum, staining was also observed in the synaptic terminals in a
Purkinje cells and granule cell layer showed significant manner similar to that seen in Purkinje cells (Fig. 7A).
fluorescence with the granule cell layer being more in- Reticular neurons of the midbrain (Fig. 8C) were also
tensely stained than the Purkinje cell (Fig. 4A). Occasional immunostained. Similar sections incubated with non-im-
staining was seen in the molecular layer. In the midbrain, mune serum did not show any staining.
reticular neurons were stained although not as intensely as
seen in the cerebellum and cortex (Fig. 4C). High levels of
CYP2D mRNA was seen in neuronal cells in the cerebral 4 . Discussion
cortex (Fig. 4E) while sections hybridized with the sense
probe showed no fluorescence (Fig. 4F). Intense fluores- The studies on effect of postmortem delay on CYP2D
cence was seen in the hippocampus (Fig. 5), in the mRNA and P450 content in rat brain revealed that the
pyramidal neurons of CA1, CA2, CA3 subfields and in the brain CYP2D mRNA was relatively stable to autolytic
granule cell layer of dentate gyrus (Fig. 5C), while similar changes that normally occur during postmortem delay. The
sections hybridized with the digoxigenin labeled sense P450 content in brain did not change significantly up to 24
probe showed no fluorescence (Fig. 5D). The pyramidal h after death in contrast to liver where significant loss of
neurons in CA1 showed intense cytosolic staining (Fig. activity was seen after 6 h. In the present study, we
5E). The neurons in CA2 were also labeled and the estimated P450 content in human autopsy brains that were
compact CA2 pyramidal cell layer was clearly discernable obtained within 12 h of postmortem delay. Presence of
(Fig. 5B). In CA3 also the pyramidal neurons were functional P450 in the autopsy brain was confirmed in
intensely fluorescent (Fig. 5C), along with the interneurons agreement with our earlier observations [1]. Northern blot
of the hilius. analyses for determining the expression of CYP2D6 was
carried out using the same brain tissue samples. Constitu-
3 .6. Immunoblot studies tive expression of CYP2D was detectable in human brain
as illustrated in Fig. 3B. The expression of CYP2D in
Immunoblot analysis of microsomes prepared from human brain had been examined earlier by using the
different regions such as, cortex, cerebellum, midbrain, polymerase chain reaction to amplify cDNA from a human
striatum and thalamus of human brain obtained at autopsy caudate lambda gt11 library encoding exons 6–9 of the
from subject 2 using antiserum to rat liver P4502D1 human CYP2D6 gene [35]. However, the present study
revealed the presence of a immunoreactive protein of provides the first evidence for the presence of the full-
molecular mass 52 kDa, thus demonstrating the constitu- length CYP2D mRNA of 1.6 Kb in human brain. CYP2D
tive expression of P4502D6 protein in various regions of is expressed relatively abundant in human brain as evi-
human brain (Fig. 6). denced from the northern blot (Fig. 3B). In humans
lacking the CYP2D6 gene (a known genetic polymor-
3 .7. Localization of P4502D by immunohistochemistry phism), both the northern and in situ hybridization studies
would have yielded negative results. However, none of the
Immunohistochemical analysis using antiserum to rat human brain samples used in the present study were
liver P4502D1demonstrated the predominant presence of polymorphic for the absence of the CYP2D6 gene.
P4502D in neuronal population in concordance with the in The localization of P4502D mRNA and protein in
situ experiments. In the cerebellum, granule cells and human brain using in situ hybridization and immuno-
Purkinje cells were stained (Fig. 7A), with the granule histochemistry demonstrated the predominant presence of
cells being more intensely stained compared to Purkinje the enzyme in the neuronal cell population in the cortex,
Fig. 8. Immunohistochemical localization of P4502D in human brain frontal cortex and midbrain using antiserum to P4502D1. (A) Intense immunolabeling
of neurons in frontal cortex was seen indicating the presence of P4502D. The arrow shows the immunostaining of the dendrites. Bar510 mm. (B) No
staining was seen in cerebral cortex section incubated with non-immune serum. Bar5100 mm. (C) Immunostaining of reticular neurons (arrow; also shown
in higher magnification in the inset) in the midbrain indicating the presence of P4502D was observed. Bar525 mm. (D) A similar section of midbrain
treated with non-immune serum did not show immunostaining. Bar5100 mm.
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Purkinje and granule cell layer of the cerebellum, granule ated with both genetic susceptibility and environmental
cell layer and pyramidal cells of the hippocampus. While factors such as exposure to pesticides [5,21,22]. Thus, the
the in situ hybridization studies provided the specific xenobiotic detoxifying capability of the brain could poten-
localization of the CYP2D mRNA (Figs. 4 and 5), tially play an important role in predisposition to certain
immunohistochemistry delineated the sub-cellular localiza- neurodegenerative diseases such as Parkinson’s disease.
tion of the P4502D protein within the neuronal cells (Figs.
6 and 7).
A close association between the dopamine transporter
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